These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 12576925

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G.
    Int J Cancer; 2002 Mar 20; 98(3):463-9. PubMed ID: 11920601
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
    Konecny GE, Thomssen C, Lück HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Möbus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ.
    J Natl Cancer Inst; 2004 Aug 04; 96(15):1141-51. PubMed ID: 15292386
    [Abstract] [Full Text] [Related]

  • 12. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S, Bear HD.
    Surg Clin North Am; 2003 Aug 04; 83(4):943-71. PubMed ID: 12875604
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
    Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR, Tortora G.
    Int J Cancer; 2000 Mar 01; 85(5):710-5. PubMed ID: 10699953
    [Abstract] [Full Text] [Related]

  • 16. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
    Ehrlichova M, Vaclavikova R, Ojima I, Pepe A, Kuznetsova LV, Chen J, Truksa J, Kovar J, Gut I.
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul 01; 372(1):95-105. PubMed ID: 16059735
    [Abstract] [Full Text] [Related]

  • 17. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
    Wang H, Vo T, Hajar A, Li S, Chen X, Parissenti AM, Brindley DN, Wang Z.
    BMC Cancer; 2014 Jan 22; 14():37. PubMed ID: 24447372
    [Abstract] [Full Text] [Related]

  • 18. Semi-synthesis of an O-glycosylated docetaxel analogue.
    Nikolakakis A, Haidara K, Sauriol F, Mamer O, Zamir LO.
    Bioorg Med Chem; 2003 Apr 03; 11(7):1551-6. PubMed ID: 12628678
    [Abstract] [Full Text] [Related]

  • 19. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
    Untch M, Untch A, Sevin BU, Angioli R, Perras JP, Koechli O, Averette HE.
    Anticancer Drugs; 1994 Feb 03; 5(1):24-30. PubMed ID: 7910494
    [Abstract] [Full Text] [Related]

  • 20. Which dosing scheme is suitable for the taxanes? An in vitro model.
    Sanli UA, Uslu R, Karabulut B, Sezgin C, Saydam G, Omay SB, Goker E.
    Arch Pharm Res; 2002 Aug 03; 25(4):550-5. PubMed ID: 12214871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.